Sarepta Says FDA Welcomes Review Of New Muscular Dystrophy Drug

Sarepta Therapeutics says regulators at the Food and Drug Administration have told it they were open to reviewing its next experimental treatment for Duchenne muscular dystrophy, meaning that it could file an application for the new medicine by the end of this year.March 12, 2018 at 07:30AM

via Forbes Real Time